GLP-1 receptor agonist therapy before bariatric surgery: Effects on weight loss and body composition in clinical practice.

Gutiérrez-Medina S, Higuera I, Velasco G, Yagüe I, Sanchez E, Lapuente F, Lopesino JM, Escalada J, Guadalix S, de la Higuera M

Obesity research & clinical practice26 May 2026Cited by 1 (Europe PMC)

PMID42191517DOI10.1016/j.orcp.2026.05.007PepBankPUB-42191517

Publisher page PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study14

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone14

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults undergoing bariatric surgery, prior pooled GLP-1 receptor agonist treatment was associated with greater preoperative weight loss than no prior GLP-1 treatment (5.1 plus or minus 4.9% versus 2.4 plus or minus 3.7%; P=0.005).
In plain wordsBefore bariatric surgery, adults with pooled GLP-1 treatment had more weight loss than adults without prior GLP-1 treatment.
Peptide
Liraglutide
Outcome
IncreasePreoperative weight loss
Study
n = 86
Comparator
No prior GLP-1 receptor agonist treatment
Outcome group
Body weight · Metabolic and weight
Measurements
Preoperative weight loss
5.1%
prior GLP-1 treatment; plus or minus 4.9
Preoperative weight loss
2.4%
no prior GLP-1 treatment; plus or minus 3.7; P=0.005
Source sentences
Summary
Patients treated with GLP1-RA achieved greater weight loss preoperatively (5.1% ± 4.9% vs. 2.4% ± 3.7%; p = 0.005) and at 1 month postoperatively (15.4% ± 5.2% vs. 13.0% ± 3.8%; p = 0.03), but not at 6 months.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of adults who underwent BS at Clínica Universidad de Navarra (Madrid) between 2017 and 2023.
Summary · context
Overall, 86 patients (mean age, 46.6 ± 12 years; 66% women) were included; 80.2% and 19.8% underwent sleeve gastrectomy and gastric bypass, respectively.
Summary · context
Preoperative GLP1-RA therapy (63.4% liraglutide and 36.6% semaglutide) was prescribed in 34.8% of patients for a mean of 21.7 ± 15.9 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4219151703
02HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults undergoing bariatric surgery, prior pooled GLP-1 receptor agonist treatment was associated with greater preoperative weight loss than no prior GLP-1 treatment (5.1 plus or minus 4.9% versus 2.4 plus or minus 3.7%; P=0.005).
In plain wordsBefore bariatric surgery, adults with pooled GLP-1 treatment had more weight loss than adults without prior GLP-1 treatment.
Peptide
Semaglutide
Outcome
IncreasePreoperative weight loss
Study
n = 86
Comparator
No prior GLP-1 receptor agonist treatment
Outcome group
Body weight · Metabolic and weight
Measurements
Preoperative weight loss
5.1%
prior GLP-1 treatment; plus or minus 4.9
Preoperative weight loss
2.4%
no prior GLP-1 treatment; plus or minus 3.7; P=0.005
Source sentences
Summary
Patients treated with GLP1-RA achieved greater weight loss preoperatively (5.1% ± 4.9% vs. 2.4% ± 3.7%; p = 0.005) and at 1 month postoperatively (15.4% ± 5.2% vs. 13.0% ± 3.8%; p = 0.03), but not at 6 months.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of adults who underwent BS at Clínica Universidad de Navarra (Madrid) between 2017 and 2023.
Summary · context
Overall, 86 patients (mean age, 46.6 ± 12 years; 66% women) were included; 80.2% and 19.8% underwent sleeve gastrectomy and gastric bypass, respectively.
Summary · context
Preoperative GLP1-RA therapy (63.4% liraglutide and 36.6% semaglutide) was prescribed in 34.8% of patients for a mean of 21.7 ± 15.9 weeks.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4219151704
03HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults undergoing bariatric surgery, prior pooled GLP-1 receptor agonist treatment was associated with greater one-month postoperative weight loss than no prior GLP-1 treatment (15.4 plus or minus 5.2% versus 13.0 plus or minus 3.8%; P=0.03).
In plain wordsOne month after bariatric surgery, adults with pooled GLP-1 treatment had more weight loss than adults without prior GLP-1 treatment.
Peptide
Liraglutide
Outcome
IncreaseWeight loss at 1 month postoperatively
Study
n = 86
Comparator
No prior GLP-1 receptor agonist treatment
Outcome group
Body weight · Metabolic and weight
Measurements
One-month postoperative weight loss
15.4%
prior GLP-1 treatment; plus or minus 5.2
One-month postoperative weight loss
13%
no prior GLP-1 treatment; plus or minus 3.8; P=0.03
Source sentences
Summary
Patients treated with GLP1-RA achieved greater weight loss preoperatively (5.1% ± 4.9% vs. 2.4% ± 3.7%; p = 0.005) and at 1 month postoperatively (15.4% ± 5.2% vs. 13.0% ± 3.8%; p = 0.03), but not at 6 months.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of adults who underwent BS at Clínica Universidad de Navarra (Madrid) between 2017 and 2023.
Summary · context
Overall, 86 patients (mean age, 46.6 ± 12 years; 66% women) were included; 80.2% and 19.8% underwent sleeve gastrectomy and gastric bypass, respectively.
Summary · context
Preoperative GLP1-RA therapy (63.4% liraglutide and 36.6% semaglutide) was prescribed in 34.8% of patients for a mean of 21.7 ± 15.9 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4219151705
04HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults undergoing bariatric surgery, prior pooled GLP-1 receptor agonist treatment was associated with greater one-month postoperative weight loss than no prior GLP-1 treatment (15.4 plus or minus 5.2% versus 13.0 plus or minus 3.8%; P=0.03).
In plain wordsOne month after bariatric surgery, adults with pooled GLP-1 treatment had more weight loss than adults without prior GLP-1 treatment.
Peptide
Semaglutide
Outcome
IncreaseWeight loss at 1 month postoperatively
Study
n = 86
Comparator
No prior GLP-1 receptor agonist treatment
Outcome group
Body weight · Metabolic and weight
Measurements
One-month postoperative weight loss
15.4%
prior GLP-1 treatment; plus or minus 5.2
One-month postoperative weight loss
13%
no prior GLP-1 treatment; plus or minus 3.8; P=0.03
Source sentences
Summary
Patients treated with GLP1-RA achieved greater weight loss preoperatively (5.1% ± 4.9% vs. 2.4% ± 3.7%; p = 0.005) and at 1 month postoperatively (15.4% ± 5.2% vs. 13.0% ± 3.8%; p = 0.03), but not at 6 months.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of adults who underwent BS at Clínica Universidad de Navarra (Madrid) between 2017 and 2023.
Summary · context
Overall, 86 patients (mean age, 46.6 ± 12 years; 66% women) were included; 80.2% and 19.8% underwent sleeve gastrectomy and gastric bypass, respectively.
Summary · context
Preoperative GLP1-RA therapy (63.4% liraglutide and 36.6% semaglutide) was prescribed in 34.8% of patients for a mean of 21.7 ± 15.9 weeks.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4219151706
05HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults undergoing bariatric surgery, pooled preoperative GLP-1 receptor agonist therapy showed no weight-loss difference at six months versus no prior GLP-1 receptor agonist treatment.
In plain wordsIn adults after bariatric surgery, pooled preoperative GLP-1 treatment showed no six-month weight loss difference versus no prior GLP-1 treatment.
Peptide
Liraglutide
Outcome
No significant changeWeight loss at 6 months postoperatively
Study
n = 86
Comparator
No prior GLP-1 receptor agonist treatment
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Patients treated with GLP1-RA achieved greater weight loss preoperatively (5.1% ± 4.9% vs. 2.4% ± 3.7%; p = 0.005) and at 1 month postoperatively (15.4% ± 5.2% vs. 13.0% ± 3.8%; p = 0.03), but not at 6 months.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of adults who underwent BS at Clínica Universidad de Navarra (Madrid) between 2017 and 2023.
Summary · context
Overall, 86 patients (mean age, 46.6 ± 12 years; 66% women) were included; 80.2% and 19.8% underwent sleeve gastrectomy and gastric bypass, respectively.
Summary · context
Preoperative GLP1-RA therapy (63.4% liraglutide and 36.6% semaglutide) was prescribed in 34.8% of patients for a mean of 21.7 ± 15.9 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4219151707
06HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults undergoing bariatric surgery, pooled preoperative GLP-1 receptor agonist therapy showed no weight-loss difference at six months versus no prior GLP-1 receptor agonist treatment.
In plain wordsIn adults after bariatric surgery, pooled preoperative GLP-1 treatment showed no six-month weight loss difference versus no prior GLP-1 treatment.
Peptide
Semaglutide
Outcome
No significant changeWeight loss at 6 months postoperatively
Study
n = 86
Comparator
No prior GLP-1 receptor agonist treatment
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Patients treated with GLP1-RA achieved greater weight loss preoperatively (5.1% ± 4.9% vs. 2.4% ± 3.7%; p = 0.005) and at 1 month postoperatively (15.4% ± 5.2% vs. 13.0% ± 3.8%; p = 0.03), but not at 6 months.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of adults who underwent BS at Clínica Universidad de Navarra (Madrid) between 2017 and 2023.
Summary · context
Overall, 86 patients (mean age, 46.6 ± 12 years; 66% women) were included; 80.2% and 19.8% underwent sleeve gastrectomy and gastric bypass, respectively.
Summary · context
Preoperative GLP1-RA therapy (63.4% liraglutide and 36.6% semaglutide) was prescribed in 34.8% of patients for a mean of 21.7 ± 15.9 weeks.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4219151708
07HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults undergoing bariatric surgery, prior pooled GLP-1 receptor agonist treatment was associated with lower preoperative fat mass than no prior GLP-1 treatment (53.3 kg, 95% CI 50.7-56.0 versus 58.6 kg, 95% CI 56.6-60.5; P=0.01).
In plain wordsBefore bariatric surgery, adults with pooled GLP-1 treatment had less fat mass than adults without prior GLP-1 treatment.
Peptide
Liraglutide
Outcome
DecreaseFat mass before bariatric surgery
Study
n = 86
Comparator
No prior GLP-1 receptor agonist treatment
Outcome group
Body composition · Metabolic and weight
Measurements
Preoperative fat mass
53.3 kg
prior GLP-1 treatment; 95% CI 50.7-56.0
Preoperative fat mass
58.6 kg
no prior GLP-1 treatment; 95% CI 56.6-60.5; P=0.01
Source sentences
Summary
Prior to BS, fat mass was lower in the GLP1-RA group (53.3 kg [95% CI 50.7-56.0] vs. 58.6 kg [95% CI 56.6-60.5]; p = 0.01), whereas no differences in lean mass or body composition were observed at 6 months between the two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of adults who underwent BS at Clínica Universidad de Navarra (Madrid) between 2017 and 2023.
Summary · context
Overall, 86 patients (mean age, 46.6 ± 12 years; 66% women) were included; 80.2% and 19.8% underwent sleeve gastrectomy and gastric bypass, respectively.
Summary · context
Preoperative GLP1-RA therapy (63.4% liraglutide and 36.6% semaglutide) was prescribed in 34.8% of patients for a mean of 21.7 ± 15.9 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4219151709
08HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults undergoing bariatric surgery, prior pooled GLP-1 receptor agonist treatment was associated with lower preoperative fat mass than no prior GLP-1 treatment (53.3 kg, 95% CI 50.7-56.0 versus 58.6 kg, 95% CI 56.6-60.5; P=0.01).
In plain wordsBefore bariatric surgery, adults with pooled GLP-1 treatment had less fat mass than adults without prior GLP-1 treatment.
Peptide
Semaglutide
Outcome
DecreaseFat mass before bariatric surgery
Study
n = 86
Comparator
No prior GLP-1 receptor agonist treatment
Outcome group
Body composition · Metabolic and weight
Measurements
Preoperative fat mass
53.3 kg
prior GLP-1 treatment; 95% CI 50.7-56.0
Preoperative fat mass
58.6 kg
no prior GLP-1 treatment; 95% CI 56.6-60.5; P=0.01
Source sentences
Summary
Prior to BS, fat mass was lower in the GLP1-RA group (53.3 kg [95% CI 50.7-56.0] vs. 58.6 kg [95% CI 56.6-60.5]; p = 0.01), whereas no differences in lean mass or body composition were observed at 6 months between the two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of adults who underwent BS at Clínica Universidad de Navarra (Madrid) between 2017 and 2023.
Summary · context
Overall, 86 patients (mean age, 46.6 ± 12 years; 66% women) were included; 80.2% and 19.8% underwent sleeve gastrectomy and gastric bypass, respectively.
Summary · context
Preoperative GLP1-RA therapy (63.4% liraglutide and 36.6% semaglutide) was prescribed in 34.8% of patients for a mean of 21.7 ± 15.9 weeks.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4219151710
09HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults undergoing bariatric surgery, pooled preoperative GLP-1 receptor agonist therapy showed no difference in lean mass at six months versus no prior GLP-1 receptor agonist treatment.
In plain wordsIn adults after bariatric surgery, pooled preoperative GLP-1 treatment showed no six-month lean mass difference versus no prior GLP-1 treatment.
Peptide
Liraglutide
Outcome
No significant changeLean mass at 6 months postoperatively
Study
n = 86
Comparator
No prior GLP-1 receptor agonist treatment
Outcome group
Body composition · Musculoskeletal
Source sentences
Summary
Prior to BS, fat mass was lower in the GLP1-RA group (53.3 kg [95% CI 50.7-56.0] vs. 58.6 kg [95% CI 56.6-60.5]; p = 0.01), whereas no differences in lean mass or body composition were observed at 6 months between the two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of adults who underwent BS at Clínica Universidad de Navarra (Madrid) between 2017 and 2023.
Summary · context
Overall, 86 patients (mean age, 46.6 ± 12 years; 66% women) were included; 80.2% and 19.8% underwent sleeve gastrectomy and gastric bypass, respectively.
Summary · context
Preoperative GLP1-RA therapy (63.4% liraglutide and 36.6% semaglutide) was prescribed in 34.8% of patients for a mean of 21.7 ± 15.9 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4219151711
10HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults undergoing bariatric surgery, pooled preoperative GLP-1 receptor agonist therapy showed no difference in lean mass at six months versus no prior GLP-1 receptor agonist treatment.
In plain wordsIn adults after bariatric surgery, pooled preoperative GLP-1 treatment showed no six-month lean mass difference versus no prior GLP-1 treatment.
Peptide
Semaglutide
Outcome
No significant changeLean mass at 6 months postoperatively
Study
n = 86
Comparator
No prior GLP-1 receptor agonist treatment
Outcome group
Body composition · Musculoskeletal
Source sentences
Summary
Prior to BS, fat mass was lower in the GLP1-RA group (53.3 kg [95% CI 50.7-56.0] vs. 58.6 kg [95% CI 56.6-60.5]; p = 0.01), whereas no differences in lean mass or body composition were observed at 6 months between the two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of adults who underwent BS at Clínica Universidad de Navarra (Madrid) between 2017 and 2023.
Summary · context
Overall, 86 patients (mean age, 46.6 ± 12 years; 66% women) were included; 80.2% and 19.8% underwent sleeve gastrectomy and gastric bypass, respectively.
Summary · context
Preoperative GLP1-RA therapy (63.4% liraglutide and 36.6% semaglutide) was prescribed in 34.8% of patients for a mean of 21.7 ± 15.9 weeks.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4219151712
11HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults undergoing bariatric surgery, pooled preoperative GLP-1 receptor agonist therapy showed no body-composition difference at six months versus no prior GLP-1 receptor agonist treatment.
In plain wordsIn adults after bariatric surgery, pooled preoperative GLP-1 treatment showed no six-month body composition difference versus no prior GLP-1 treatment.
Peptide
Liraglutide
Outcome
No significant changeBody composition at 6 months postoperatively
Study
n = 86
Comparator
No prior GLP-1 receptor agonist treatment
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Prior to BS, fat mass was lower in the GLP1-RA group (53.3 kg [95% CI 50.7-56.0] vs. 58.6 kg [95% CI 56.6-60.5]; p = 0.01), whereas no differences in lean mass or body composition were observed at 6 months between the two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of adults who underwent BS at Clínica Universidad de Navarra (Madrid) between 2017 and 2023.
Summary · context
Overall, 86 patients (mean age, 46.6 ± 12 years; 66% women) were included; 80.2% and 19.8% underwent sleeve gastrectomy and gastric bypass, respectively.
Summary · context
Preoperative GLP1-RA therapy (63.4% liraglutide and 36.6% semaglutide) was prescribed in 34.8% of patients for a mean of 21.7 ± 15.9 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4219151713
12HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults undergoing bariatric surgery, pooled preoperative GLP-1 receptor agonist therapy showed no body-composition difference at six months versus no prior GLP-1 receptor agonist treatment.
In plain wordsIn adults after bariatric surgery, pooled preoperative GLP-1 treatment showed no six-month body composition difference versus no prior GLP-1 treatment.
Peptide
Semaglutide
Outcome
No significant changeBody composition at 6 months postoperatively
Study
n = 86
Comparator
No prior GLP-1 receptor agonist treatment
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Prior to BS, fat mass was lower in the GLP1-RA group (53.3 kg [95% CI 50.7-56.0] vs. 58.6 kg [95% CI 56.6-60.5]; p = 0.01), whereas no differences in lean mass or body composition were observed at 6 months between the two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of adults who underwent BS at Clínica Universidad de Navarra (Madrid) between 2017 and 2023.
Summary · context
Overall, 86 patients (mean age, 46.6 ± 12 years; 66% women) were included; 80.2% and 19.8% underwent sleeve gastrectomy and gastric bypass, respectively.
Summary · context
Preoperative GLP1-RA therapy (63.4% liraglutide and 36.6% semaglutide) was prescribed in 34.8% of patients for a mean of 21.7 ± 15.9 weeks.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4219151714
13HumanNot a test of Liraglutide aloneObservational studySafety outcome
In adults undergoing bariatric surgery with preoperative GLP-1 receptor agonist therapy, adverse events were mild and mostly gastrointestinal symptoms.
In plain wordsIn adults undergoing bariatric surgery, pooled preoperative liraglutide/semaglutide treatment was linked to mild, mostly gastrointestinal side effects.
Peptide
Liraglutide
Outcome
Not applicableGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Adverse events were mild and mostly gastrointestinal symptoms.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of adults who underwent BS at Clínica Universidad de Navarra (Madrid) between 2017 and 2023.
Summary · context
Overall, 86 patients (mean age, 46.6 ± 12 years; 66% women) were included; 80.2% and 19.8% underwent sleeve gastrectomy and gastric bypass, respectively.
Summary · context
Preoperative GLP1-RA therapy (63.4% liraglutide and 36.6% semaglutide) was prescribed in 34.8% of patients for a mean of 21.7 ± 15.9 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4219151701
14HumanNot a test of Semaglutide aloneObservational studySafety outcome
In adults undergoing bariatric surgery with preoperative GLP-1 receptor agonist therapy, adverse events were mild and mostly gastrointestinal symptoms.
In plain wordsIn adults undergoing bariatric surgery, pooled preoperative liraglutide/semaglutide treatment was linked to mild, mostly gastrointestinal side effects.
Peptide
Semaglutide
Outcome
Not applicableGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Adverse events were mild and mostly gastrointestinal symptoms.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of adults who underwent BS at Clínica Universidad de Navarra (Madrid) between 2017 and 2023.
Summary · context
Overall, 86 patients (mean age, 46.6 ± 12 years; 66% women) were included; 80.2% and 19.8% underwent sleeve gastrectomy and gastric bypass, respectively.
Summary · context
Preoperative GLP1-RA therapy (63.4% liraglutide and 36.6% semaglutide) was prescribed in 34.8% of patients for a mean of 21.7 ± 15.9 weeks.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4219151702

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.